Sterling Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Sterling Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.36K	Sell	593 -350	-37%	-$3.36K	﹤0.01%	2695
2026 Q1	$11.9K	Sell	943 -697	-43%	-$7.99K	﹤0.01%	2283
2025 Q4	$16.9K	Sell	1,640 -301	-16%	-$2.54K	﹤0.01%	2322
2025 Q3	$11.3K	Buy	1,941 +1,244	+178%	+$7.28K	﹤0.01%	2426
2025 Q2	$4.68K	Buy	697 +271	+64%	+$2.18K	﹤0.01%	2546
2025 Q1	$3.85K	Sell	426 -366	-46%	-$4.56K	﹤0.01%	2289
2024 Q4	$13.7K	Buy	792 +702	+780%	+$12.7K	﹤0.01%	2012
2024 Q3	$1.44K	Buy	+90	New	+$1.42K	﹤0.01%	2356

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Sterling Capital Management's TRDA Position: Q2 2026 in Review

Sterling Capital Management reduced its Entrada Therapeutics (TRDA) stake by 37% in Q2 2026, selling an estimated $3.36K and leaving 593 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

Sterling Capital Management first reported a position in TRDA in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.9K in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Sterling Capital Management held 593 shares of Entrada Therapeutics worth $4.36K as of Q2 2026.
Sterling Capital Management sold 350 Entrada Therapeutics shares in Q2 2026, an estimated $3.36K.
Entrada Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2695 holding.
Sterling Capital Management first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Entrada Therapeutics position peaked at $16.9K in Q4 2025.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.